Evolus, Inc. (EOLS)
Pre-Market:
| Previous Close | 10.51 |
| Open | 10.60 |
| Bid | 10.44 x 200 |
| Ask | 10.48 x 400 |
| Day's Range | 10.39 - 10.60 |
| 52 Week Range | 7.07 - 15.43 |
| Volume | |
| Avg. Volume | 541,637 |
| Market Cap | 654.28M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.29 |
Business WireEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
NEWPORT BEACH, Calif., June 24, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).
Simply Wall St.Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)
We feel now is a pretty good time to analyse Evolus, Inc.'s ( NASDAQ:EOLS ) business as it appears the company may be...
Business WireEvolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
NEWPORT BEACH, Calif., June 12, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals.
